NCT02151110

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
BIOLOGICAL	MEDI4920 3 mg	Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
BIOLOGICAL	MEDI4920 10 mg	Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
BIOLOGICAL	MEDI4920 30 mg	Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
BIOLOGICAL	MEDI4920 100 mg	Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
BIOLOGICAL	MEDI4920 300 mg	Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
BIOLOGICAL	MEDI4920 1000 mg	Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
BIOLOGICAL	MEDI4920 3000 mg	Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
OTHER	Placebo	Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.

Timeline

• Start date: 2014-05-27
• Primary completion: 2016-05-09
• Completion: 2016-05-09
• First posted: 2014-05-30
• Last updated: 2019-02-15
• Results posted: 2019-02-15

Locations

1 site across 1 country: United Kingdom